AN2 Therapeutics 13G filing shows stake on 15 May reported

Form 13G reporting for AN2 Therapeutics was filed with a report date of 15 May 2026, according to Investing.com. The short notice flags a passive ownership disclosure rather than an activist intent and contains standard SEC cover-page details. Investors and data desks should consult the SEC filing directly for the filer name and share count. This article explains what that 13G filing signifies and what to check next.

What does the 13G filed for AN2 Therapeutics state?

The filing reported on 15 May 2026 is a Schedule 13G submission, the SEC form used for passive beneficial-ownership disclosures once an investor crosses the 5% threshold. The document's cover page will list the filing date and the filer’s signature block; those two items are recorded as primary identifiers. Typical 13G cover pages also show the number of shares and the percentage of outstanding stock, both essential for assessing ownership scale.

Who is likely the filer and how big is the stake?

The brief report did not include the filer name or share count in its headline; the full EDGAR submission contains the exact numbers and the filer identity. A 13G is used when an investor holds more than 5% of a class of stock in a passive capacity, so the relevant threshold to watch is 5 percent. To confirm the owner and holdings, retrieve the filing's exhibit pages on SEC EDGAR and note the precise share total and percentage.

How should trading desks and quant models treat a 13G disclosure?

A Schedule 13G is typically treated as a disclosure of passive ownership and not evidence of an intention to change corporate control, so many algorithmic desks assign lower short-term signals. Quant strategies that scan filings will flag the filing date — here 15 May — and ingest the share count and percent from the filing’s table of beneficial ownership. Risk desks will still record a position change of 5% or greater in their compliance logs because regulatory thresholds kick in at that level.

What checks should investors run after a 13G appears?

Step one is to verify the filing on SEC EDGAR and extract the exact share total and percentage; those two numbers determine whether the filer crossed the 5% reporting trigger. Step two is to check whether the filer is an institutional investor, which often means passive intent, or an insider or activist with different consequences. Finally, review any related filings filed within 1 to 30 days that could amend or clarify the initial 13G.

Limitation and risk

The short published notice does not substitute for the primary SEC filing. This piece does not state the filer name or share count because the headline-only report lacked those specifics; reliance on the cover notice alone can understate ownership scale and timing risk.

Q: Where can I read the full 13G for AN2 Therapeutics?

Search SEC EDGAR by company ticker or the company’s 10-digit CIK to pull the exact Schedule 13G document; EDGAR lists the filing date and provides the full cover page, holdings table and signature page. For ongoing monitoring, link filings into your data pipeline so each 13G is archived with its filing date — here, 15 May 2026 — and the reported share count is stored as a numeric field.

Q: Does a 13G mean the filer will try to control the company?

No. A Schedule 13G is the disclosure vehicle for passive investors who exceed the 5% threshold and do not intend to exert control. Investors who intend to influence management must file a Schedule 13D instead, which requires more detailed intent disclosure and can trigger additional market and governance scrutiny.

Bottom Line

Treat the 13G for AN2 Therapeutics dated 15 May 2026 as a passive ownership disclosure and verify the SEC filing for exact share counts.

insider filings and ownership disclosures should be added to corporate-monitoring feeds to capture the exact numbers disclosed in the EDGAR submission.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.